Case Studies

2025-06-20

AtaGenix Delivers Custom RMP and IKKβ Protein Expression Services for Naval Medical University’s Sepsis Research

AtaGenix Laboratories Co., Ltd. partnered with Naval Medical University researchers to provide custom protein expression services for a sepsis study published in Cell Communication and Signaling (DOI: 10.1186/s12964-025-02278-w). The study demonstrated that RNA polymerase II subunit 5-mediating protein (RMP) inhibits TLR4-induced NF-κB signaling in macrophages by binding IκB kinase β (IKKβ) and recruiting protein phosphatase 2A (PP2A). AtaGenix delivered high-purity GST, GST-mouse RMP-WT, GST-mouse RMP-S439A, and His-mouse IKKβ proteins using an E. coli expression system, validated via Western blot (WB). These proteins supported surface plasmon resonance (SPR), GST-pulldown, and ADP-Glo kinase assays, confirming RMP’s role in modulating inflammation and its potential as a therapeutic target for sepsis.

2025-06-20

AtaGenix Provides Custom PRPF19 Protein Expression Services for Huazhong University of Science and Technology’s Diabetic Nephropathy Research

AtaGenix Laboratories Co., Ltd. partnered with researchers at Huazhong University of Science and Technology to provide custom PRPF19 protein expression services for a study on diabetic nephropathy (DN) published in Cell Communication and Signaling (DOI: 10.1186/s12964-025-02253-5). The study elucidated the role of PRPF19 in mediating ubiquitin-dependent degradation of vitamin D receptor (VDR), exacerbating ferroptosis in renal tubular epithelial cells (RTECs). AtaGenix delivered high-purity PRPF19 protein (1.67 mg/ml) for surface plasmon resonance (SPR) studies, validated through Western blot (WB) and immunoprecipitation (IP) assays. The protein enabled the team to confirm berberine (BBR) as a PRPF19 inhibitor, offering a novel therapeutic approach to mitigate DN by reducing ferroptosis.

2025-06-20

AtaGenix Delivers Custom Rabbit Polyclonal Antibody Services for Haojie Hao’s Team at Wuhan Institute of Virology

AtaGenix Laboratories Co., Ltd. collaborated with the research team led by Haojie Hao at the Wuhan Institute of Virology to develop a custom mouse polyclonal antibody (pAb) against the Nipah virus (NiV) M protein, supporting a groundbreaking study published in Viruses (DOI: 10.3390/v17060831, IF: 3.8 Q2). The study revealed the critical role of N6-methyladenosine (m6A) modification in enhancing NiV replication and pathogenicity, particularly in the NiV-Malaysia strain. By designing specific antigens and delivering high-titer pAbs validated through Western blot assays in biosafety level 4 (BSL-4) conditions, AtaGenix enabled the team to confirm the M protein’s role in modulating host m6A machinery, advancing antiviral research.

2025-05-30

Professional Protein Expression and Antibody Customization Services to Support High-Impact Research on UGT Gene Family in Platycodon grandiflorus

A study identified 107 UGT genes in Platycodon grandiflorus, with PgUGT29 catalyzing the glycosylation of Platycodin D to D3. AtaGenix provides tailored protein expression and antibody customization, ensuring high-purity PgUGT29 (>95%) and specific anti-PgUGT29 antibodies for functional validation via HPLC and molecular docking, advancing saponin biosynthesis research.

2025-05-30

Professional Protein Expression and Antibody Customization Services for Grass Carp C5a-CP Adjuvant Research

Grass carp C5a-CP shows exceptional potential as a vaccine adjuvant, enhancing IgM⁺ B cell phagocytic activity and vaccine efficacy. We provide professional protein expression and antibody customization services, including IgM-CH expression and purification and anti-C5aR polyclonal antibody production, supporting functional validation with high purity and specificity to advance fish vaccine adjuvant research.

2024-11-05

Antibody Fragment Production

Using AtaGenix's mammalian cell expression system, various antibody fragments have been successfully expressed, including scFv, VHH, Fab, and scFv-Fc-scFv, meeting diverse research and development needs.The accompanying images demonstrate the expression results and workflow of antibody production using this advanced system.

2024-11-05

Stable Cell Line Development for Antibodies and Viral Proteins | AtaGenix Case Studies

Explore AtaGenix case studies on recombinant protein expression, including CHO stable cell lines achieving >3 g/L antibody yields and Bacillus subtilis systems for Protein A and B production. Data validated by SDS-PAGE, stability, purity, and affinity assays highlight AtaGenix’s expertise in high-quality protein expression solutions.

2024-11-05

Large-Scale Recombinant Antibody Production

Using AtaGenix's proprietary XtenCHO™ mammalian expression system, full-length IgG, VHH, scFv, and Fab antibody fragments were successfully expressed. The accompanying SDS-PAGE analysis demonstrates the system's ability to produce high-quality proteins:

2024-11-05

Chimeric Antibody Expression and Validation | AtaGenix Custom Antibody Development Services

Chimeric antibody production combines the variable region of one species with the constant region of another to achieve optimal specificity and functionality. This approach ensures high binding affinity while maintaining robust stability and compatibility with downstream applications. Utilizing cutting-edge expression systems, production is scalable, cost-effective, and delivers high-purity antibodies suitable for therapeutic and research purposes.

2024-11-05

Bispecific Antibody Development

This case study showcases the quality and functionality assessment of Dubody bispecific antibodies through QC, SEC-HPLC monomer purity, and ELISA titer analysis. The results confirm high purity and robust activity, supporting their application in therapeutic development.

2024-11-05

Protein A and Protein B Expression in Bacillus subtilis | High-Purity Recombinant Protein Solutions by AtaGenix

Discover how AtaGenix optimized Protein A secretion and Protein B intracellular expression in Bacillus subtilis. Case studies show high yields and >90% purity validated by SDS-PAGE, highlighting AtaGenix’s expertise in recombinant protein expression and quality control.

2024-11-05

HLA-I Expression and pMHC Tetramer Assembly in E. coli | AtaGenix

HLA-I protein and β2M were expressed and purified in E. coli, followed by refolding to form stable HLA/β2M/peptide complexes (pMHC). The addition of streptavidin (SA) enabled the formation of stable tetramers for downstream applications.